KR102882178B1 - 신규한 디펩티드 화합물과 이의 용도 - Google Patents
신규한 디펩티드 화합물과 이의 용도Info
- Publication number
- KR102882178B1 KR102882178B1 KR1020217016217A KR20217016217A KR102882178B1 KR 102882178 B1 KR102882178 B1 KR 102882178B1 KR 1020217016217 A KR1020217016217 A KR 1020217016217A KR 20217016217 A KR20217016217 A KR 20217016217A KR 102882178 B1 KR102882178 B1 KR 102882178B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862751984P | 2018-10-29 | 2018-10-29 | |
| US62/751,984 | 2018-10-29 | ||
| PCT/US2019/057985 WO2020092139A1 (en) | 2018-10-29 | 2019-10-25 | Novel dipeptide compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210086682A KR20210086682A (ko) | 2021-07-08 |
| KR102882178B1 true KR102882178B1 (ko) | 2025-11-05 |
Family
ID=70464360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217016217A Active KR102882178B1 (ko) | 2018-10-29 | 2019-10-25 | 신규한 디펩티드 화합물과 이의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12209141B2 (https=) |
| EP (1) | EP3873916B8 (https=) |
| JP (1) | JP7503561B2 (https=) |
| KR (1) | KR102882178B1 (https=) |
| CN (2) | CN116813691B (https=) |
| AU (1) | AU2019371209B2 (https=) |
| CA (1) | CA3117599A1 (https=) |
| IL (1) | IL282676B1 (https=) |
| TW (1) | TWI870362B (https=) |
| WO (1) | WO2020092139A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3117599A1 (en) * | 2018-10-29 | 2020-05-07 | Huahai Us Inc. | Novel dipeptide compounds and uses thereof |
| CN118496301A (zh) * | 2023-02-16 | 2024-08-16 | 丽珠医药集团股份有限公司 | 一种二肽类化合物的盐、其制备方法和用途 |
| WO2024169765A1 (zh) * | 2023-02-16 | 2024-08-22 | 上海华汇拓医药科技有限公司 | 一种二肽类化合物的盐、其制备方法和用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| MX9201416A (es) * | 1991-03-28 | 1992-10-01 | Rhone Poulenc Rorer Int | Peptidos y pseudopeptidos antitromboticos. |
| JP4561696B2 (ja) * | 1994-01-27 | 2010-10-13 | 三菱化学株式会社 | プロリンアミド誘導体 |
| FR2793248B1 (fr) * | 1999-05-03 | 2001-06-29 | Adir | Nouveaux derives de 2,3-methano-aminoacides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6774110B2 (en) * | 2001-03-19 | 2004-08-10 | Lg Life Sciences Ltd. | Orally available peptidic thrombin inhibitors |
| FR2836143B1 (fr) * | 2002-02-21 | 2004-04-16 | Servier Lab | Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10339862A1 (de) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| EP1778616A1 (en) * | 2004-08-09 | 2007-05-02 | Cancer Research Technology Limited | Alpha-ketoglutarates and their use as therapeutic agents |
| DE102004062864A1 (de) | 2004-12-21 | 2006-06-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Folienbehälter |
| CN100502914C (zh) * | 2005-10-24 | 2009-06-24 | 丽珠医药集团股份有限公司 | 一种治疗脑中风的中药组合物及其制备方法 |
| MX2008012574A (es) * | 2006-03-29 | 2008-10-10 | Schering Corp | Derivados de himbacina monociclitos y biciclicos utiles como antagonistas del receptor de trombina. |
| CN101784516B (zh) * | 2007-06-13 | 2014-07-02 | 百时美施贵宝公司 | 作为凝血因子抑制剂的二肽类似物 |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| CN102464701B (zh) * | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | 一类新型化合物、其制备方法及用途 |
| CN102796168B (zh) * | 2011-05-27 | 2014-02-26 | 首都医科大学 | 一种具有溶血栓活性的化合物，及其制备方法和应用 |
| CN103833827B (zh) * | 2012-11-27 | 2016-08-03 | 上海医药工业研究院 | 一种酰胺类化合物、其药物组合物、制备方法及应用 |
| AU2014278172B2 (en) * | 2013-06-12 | 2018-08-09 | Mycovia Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| CN106316975A (zh) * | 2015-06-15 | 2017-01-11 | 山东轩竹医药科技有限公司 | 酰胺类化合物及其作为tgr5激动剂的应用 |
| CA3117599A1 (en) * | 2018-10-29 | 2020-05-07 | Huahai Us Inc. | Novel dipeptide compounds and uses thereof |
-
2019
- 2019-10-25 CA CA3117599A patent/CA3117599A1/en active Pending
- 2019-10-25 AU AU2019371209A patent/AU2019371209B2/en active Active
- 2019-10-25 WO PCT/US2019/057985 patent/WO2020092139A1/en not_active Ceased
- 2019-10-25 KR KR1020217016217A patent/KR102882178B1/ko active Active
- 2019-10-25 US US17/289,379 patent/US12209141B2/en active Active
- 2019-10-25 CN CN202310778549.2A patent/CN116813691B/zh active Active
- 2019-10-25 CN CN201980082261.3A patent/CN113195515B/zh active Active
- 2019-10-25 JP JP2021547662A patent/JP7503561B2/ja active Active
- 2019-10-25 EP EP19877652.8A patent/EP3873916B8/en active Active
- 2019-10-28 TW TW108138880A patent/TWI870362B/zh active
-
2021
- 2021-04-27 IL IL282676A patent/IL282676B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022509366A (ja) | 2022-01-20 |
| IL282676A (en) | 2021-06-30 |
| US12209141B2 (en) | 2025-01-28 |
| JP7503561B2 (ja) | 2024-06-20 |
| CN113195515A (zh) | 2021-07-30 |
| EP3873916C0 (en) | 2025-02-19 |
| US20210395299A1 (en) | 2021-12-23 |
| CA3117599A1 (en) | 2020-05-07 |
| AU2019371209B2 (en) | 2025-05-01 |
| EP3873916A1 (en) | 2021-09-08 |
| EP3873916B8 (en) | 2025-03-26 |
| IL282676B1 (en) | 2026-03-01 |
| CN116813691A (zh) | 2023-09-29 |
| EP3873916A4 (en) | 2022-08-10 |
| AU2019371209A1 (en) | 2021-05-27 |
| KR20210086682A (ko) | 2021-07-08 |
| TW202031674A (zh) | 2020-09-01 |
| EP3873916B1 (en) | 2025-02-19 |
| TWI870362B (zh) | 2025-01-21 |
| CN113195515B (zh) | 2024-11-15 |
| CN116813691B (zh) | 2024-04-12 |
| WO2020092139A1 (en) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69931393T2 (de) | Antithrombotische amide | |
| JP6154473B2 (ja) | 第ＸＩａ因子阻害剤の結晶形 | |
| EP2611779B1 (en) | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR | |
| KR102882178B1 (ko) | 신규한 디펩티드 화합물과 이의 용도 | |
| DE60114640T2 (de) | Antithrombosemittel | |
| CN101421242B (zh) | 二酰胺衍生物 | |
| RU2731618C2 (ru) | Нестероидные модуляторы глюкокортиодидных рецепторов для местной доставки лекарств | |
| HK40060683A (en) | Novel dipeptide compounds and uses thereof | |
| HK40060683B (en) | Novel dipeptide compounds and uses thereof | |
| US20250179118A1 (en) | Novel dipeptide compounds and uses thereof | |
| HK40094572A (zh) | 新的二肽类化合物及其用途 | |
| HK40094572B (zh) | 新的二肽类化合物及其用途 | |
| KR102670554B1 (ko) | 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물 | |
| JP2002526531A (ja) | トロンビン阻害剤としてのベンズアミド誘導体 | |
| KR100377558B1 (ko) | 피페리딘 작용기를 갖는 선택적 트롬빈 억제제 | |
| JP2011073993A (ja) | 抗凝固作用を有するキノキサリンカルボキサミド誘導体 | |
| HK1212333B (en) | Crystalline forms of a factor xia inhibitor | |
| HK1186181B (en) | Crystalline forms of a factor xa inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |